Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
7,341 total articles
Revolution Medicines President and CEO Mark A. Goldsmith sold 12,871 shares on March 17, 2026, under a pre-set 10b5-1 plan to cover taxes tied to RSU vesting. The transaction amounted to roughly $1.28 million and occurred while the stock traded close to its 52-week high. The company recently reported a wider net loss for Q4 2025 and retains more ca…
Revolution Medicines Chief Operating Officer Margaret A. Horn executed a planned sale of 4,583 common shares on March 17, 2026, generating $455,918. The transaction occurred as RVMD shares trade close to their 52-week high. The company recently reported a wider quarterly loss driven by elevated R&D spending and has drawn multiple analyst reactions …
A consortium including Pale Fire Capital entities and two individuals purchased 1,602,505 shares of Phreesia, Inc. (NASDAQ: PHR) between March 17 and March 19, 2026, for a total of $18.3 million. The transactions increased the group's holdings to 7,648,829 shares. The activity coincides with Phreesia's recent refinancing of its bridge loan, a produ…
Jeff Cislini, general counsel of Revolution Medicines, sold 2,958 shares of the company's common stock in two trades on March 17 and March 19, 2026, receiving about $291,889. The March 17 sale was executed under a 10b5-1 instruction letter adopted in May 2023 to cover tax obligations from restricted stock unit vesting; the March 19 sale followed a …
Xiaolin Wang, Executive Vice President of Clinical Development at Revolution Medicines, sold 2,010 shares on March 17, 2026, generating proceeds of $199,955. The transaction was carried out under a Rule 10b5-1 trading plan put in place November 17, 2025, to cover taxes from restricted stock unit vesting. The move comes while RVMD shares trade close…
Revolution Medicines CFO Jack Anders sold 2,753 shares on March 17, 2026, generating $273,869 in proceeds under a pre-arranged Rule 10b5-1 plan. The move comes as RVMD shares trade close to their 52-week high after a 156% gain year-over-year. The company reported a wider-than-expected Q4 2025 loss driven by higher research and development and SG&A …
Alignment Healthcare Chief Operating Officer Sebastian Burzacchi sold 15,361 shares of common stock on March 18, 2026, in a transaction tied to tax withholding for vested restricted stock units. The shares were disposed at a weighted-average price of $17.84, netting $274,040. The company recently reported strong fourth-quarter growth and faces a pl…
CytomX Therapeutics Chief Medical Officer Yu-Waye Chu sold 21,279 shares on March 17, 2026, raising $136,675 to satisfy tax liabilities tied to vesting restricted stock units. The price per share in the sale was $6.423, a premium to the firm's recent market quote. Separately, CytomX announced a $250 million common stock and pre-funded warrant offer…
Ambarella Inc.'s CFO John Alexander Young sold a total of 7,615 Ordinary Shares in two transactions in March 2026, netting roughly $406,005, while also acquiring shares through the exercise of performance stock units and receipt of vested restricted stock units. The moves coincide with the company's fourth-quarter fiscal 2026 results that slightly …
Ambarella Inc. CEO Feng-Ming Wang completed a series of equity transactions between March 17 and March 19, 2026, resulting in the sale of 27,059 shares for about $1.44 million. The moves included the exercise of Performance Stock Units, tax-covering share sales, and receipt of shares as bonus payment. These insider actions coincide with recent quar…
Ambarella Inc.'s Chief Operations Officer Lee Chan W. disposed of 10,370 ordinary shares in two trades on March 17 and March 19, 2026, generating roughly $552,213. The transactions - executed at prices between $52.77 and $54.14 per share - were performed to satisfy tax obligations stemming from the vesting of restricted stock units. The insider act…
Alignment Healthcare Chief Executive Officer John E. Kao sold 73,046 shares on March 18, 2026, generating roughly $1.3 million to satisfy tax withholding tied to restricted stock unit vesting. The sale was not a discretionary trade. The company reported robust fourth-quarter results with membership and revenue gains, while a 13.2 million-share seco…
Globalstar, Inc. (NASDAQ:GSAT) Chief Executive Officer Paul E. Jacobs reported a sale of $42,525 in company shares on March 19, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The filing shows Jacobs sold 714 shares of Voting Common Stock at prices between $59.56 and $59.5816. On the same date he exercised options to…
Alignment Healthcare Chief Medical Officer Kim Hyong sold 18,404 shares of the company's common stock on March 18, 2026, in a transaction executed to satisfy tax withholding obligations tied to the vesting of restricted stock units. The sale, which was non-discretionary, fetched a weighted-average price of $17.84 per share for a total of $328,327. …
SentinelOne CEO Tomer Weingarten sold 38,864 Class A shares on March 17, 2026, for about $562,350 under a Rule 10b5-1 plan. The cybersecurity firm reported fourth-quarter fiscal 2026 revenue in line with expectations and 22% year-over-year revenue growth, but it is still unprofitable and its shares have slipped 25% over the past year. Several analy…
On March 18, 2026, Silver Lake Technology Investors V, L.P. and affiliated entities sold a total of $3.97 million in Dell Technologies Inc. (DELL) Class C common stock across two execution prices. The sales were executed in several tranches at weighted-average prices of $154.17 and $154.78 per share. Dell’s shares have risen 62% over the prior year…
CytomX Therapeutics CEO Sean A. McCarthy sold 118,969 shares on March 17, 2026, at $6.423 per share for $764,137 to meet tax obligations tied to the vesting of restricted stock units. The transaction leaves him with just over 1.07 million shares directly and an additional indirect holding in a family trust. The move occurs as the company advances a…
A group of Silver Lake-related entities disposed of $11.3 million of Dell Technologies Inc Class C Common Stock on March 18, 2026, after converting Class B shares into Class C at a conversion price of $0. The sales occurred in a $150.32 to $152.90 per share range. Dell shares have since risen to $156.76, marking nearly a 62% gain over the past year…
A group of Silver Lake investment vehicles sold 74,782 shares of Dell Technologies Class C stock on March 18, 2026, realizing roughly $11.3 million at prices between $150.32 and $152.90. The same entities converted 136,931 Class B shares into Class C shares. Dell shares have since risen to $156.76, with the company cited as undervalued by an invest…
Silver Lake Group and affiliated investment vehicles sold approximately $3.9 million of Dell Technologies Inc. (NASDAQ: DELL) Class C Common Stock on March 18, 2026, across two price points. The filings show in-kind distributions and conversions tied to the transactions, while Dell continues to report strong AI infrastructure demand and declared a …
Edward Smolyansky, who holds roughly 10% of Lifeway Foods, sold 14,353 shares on March 19, 2026, at a weighted average price of $17.77, generating $255,052 in proceeds. The trade occurred while the stock was trading near its 52-week low. Lifeway also reported fourth-quarter 2025 results that missed analyst expectations on both EPS and revenue, alth…
Alignment Healthcare Chief Information Officer Robert L. Scavo sold 11,285 shares on March 18, 2026 at a weighted-average price of $17.84, raising $201,324 to satisfy tax withholding tied to vested restricted stock units. The sale was non-discretionary. The company recently reported robust fourth-quarter growth and faces a 13.2 million share second…
Ludmila Smolyansky sold 10,000 shares of Lifeway Foods Inc (NASDAQ:LWAY) on March 18, 2026, generating $187,399 from transactions executed between $18.42 and $19.34 per share. The sale arrives while the stock trades close to a 52-week low and after the company reported fourth-quarter 2025 results that fell short of analyst expectations on both EPS …
Alignment Healthcare Chief Human Resources Officer Andreas P. Wagner sold a combined 23,602 shares of the company's common stock in two transactions on March 18 and 19, 2026, generating approximately $425,476 in proceeds. One sale covered tax withholding on vested restricted stock units and was non-discretionary; the other was executed under a pre-…
Marcia Belvin, Senior Vice President and Chief Scientific Officer of CytomX Therapeutics, sold 31,492 shares on March 17, 2026, in a transaction disclosed on a Form 4. The sale, executed at $6.423 per share to meet tax obligations from restricted stock unit vesting, generated $202,273. CytomX is also pursuing a $250 million public offering as it ad…
